Androgen Receptor Controls EGFR and ERBB2 Gene Expression at Different Levels in Prostate Cancer Cell Lines

Prostate cancer is the most commonly diagnosed non-cutaneous malignancy in men in developed countries. At diagnosis most prostate cancers are androgen dependent, meaning their growth, survival and progression are driven by the androgen-activated androgen receptor. This application note describes a study on androgenic regulation of EGFR and ERBB2 expression in prostate cancer cell lines presenting different androgen sensitivities. Inhibition of local androgen production could be an efficient way to stop the progression of prostate cancer, similar to treatment of breast cancers using aromatase inhibitors.